GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BGI Genomics Co Ltd (SZSE:300676) » Definitions » EV-to-EBITDA

BGI Genomics Co (SZSE:300676) EV-to-EBITDA : 70.15 (As of May. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BGI Genomics Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BGI Genomics Co's enterprise value is ¥12,095 Mil. BGI Genomics Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥172 Mil. Therefore, BGI Genomics Co's EV-to-EBITDA for today is 70.15.

The historical rank and industry rank for BGI Genomics Co's EV-to-EBITDA or its related term are showing as below:

SZSE:300676' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.53   Med: 45.8   Max: 193.09
Current: 71.12

During the past 12 years, the highest EV-to-EBITDA of BGI Genomics Co was 193.09. The lowest was 11.53. And the median was 45.80.

SZSE:300676's EV-to-EBITDA is ranked worse than
93.86% of 114 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.305 vs SZSE:300676: 71.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), BGI Genomics Co's stock price is ¥39.20. BGI Genomics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.165. Therefore, BGI Genomics Co's PE Ratio for today is 237.58.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


BGI Genomics Co EV-to-EBITDA Historical Data

The historical data trend for BGI Genomics Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BGI Genomics Co EV-to-EBITDA Chart

BGI Genomics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.94 16.80 12.92 10.31 24.26

BGI Genomics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.68 45.94 56.73 24.26 75.14

Competitive Comparison of BGI Genomics Co's EV-to-EBITDA

For the Diagnostics & Research subindustry, BGI Genomics Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BGI Genomics Co's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BGI Genomics Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BGI Genomics Co's EV-to-EBITDA falls into.



BGI Genomics Co EV-to-EBITDA Calculation

BGI Genomics Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=12094.773/172.401
=70.15

BGI Genomics Co's current Enterprise Value is ¥12,095 Mil.
BGI Genomics Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥172 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BGI Genomics Co  (SZSE:300676) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BGI Genomics Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=39.20/0.165
=237.58

BGI Genomics Co's share price for today is ¥39.20.
BGI Genomics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.165.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


BGI Genomics Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BGI Genomics Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BGI Genomics Co (SZSE:300676) Business Description

Traded in Other Exchanges
N/A
Address
21 Hongan Third Street, Dong, Huada Complex Park, Yantian District, Shenzhen, CHN, 518083
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Executives
Wang Jian Director
Liu Na Executives
Sun Ying Jun Director
Yin Ye Directors, executives
Du Yu Tao Directors, executives
Li Song Gang Supervisors
Hu Yu Jie Supervisors
Xu Qian Secretary Dong
Li Zhi Ping Executives
Chen Yi Qing Executives
Li Wen Qi Supervisors

BGI Genomics Co (SZSE:300676) Headlines

No Headlines